Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

SPACTORY, revolutionising pharmaceutical development and manufacturing through microgravity

Objectif

Over 2,000 R&D experiments have been done in Space until now. Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments. The low-gravity accelerates the development and preclinical testing of complex molecules –e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patient’s lives and improving their QoL.
To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space. MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher. For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-EIC-2024-ACCELERATOR-02

Voir tous les projets financés au titre de cet appel

Coordinateur

SPACEPHARMA R&D ISRAEL LTD
Contribution nette de l'UE
€ 2 184 052,50
Adresse
Abba Eban 1
4672519 Herzliya Pituach
Israël
PME
Oui
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée